Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
The 2023 audited Financial Statement for RVX should be due at month's end, March 31, 2024.
Anxious to see how much financial support RVX is getting from Zenith to keep the light on.
Zenith's 3rd quarter filings (January 31, 2024) are overdue.
Koo